We have advised MDAX-listed Evotec SE (Evotec), a global biotechnology company committed to advancing drug discovery and development, on structuring and raising its inaugural syndicated revolving credit facility (RCF). The financing package was provided by a consortium of seven international banks, and this new syndicated facility will support Evotec in pursuing its operational and strategic goals in the upcoming years.
Headquartered in Hamburg, Evotec is dedicated to discovering, developing, and manufacturing medicines for patients worldwide. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies. Evotec focuses on data-driven precision medicine and early disease relevance in humans to bring up probabilities of success. By bringing together the best minds, AI-powered and data-driven approaches, and state-of-the-art technologies, together with its partners, Evotec achieves transformative results to create highly effective therapeutics for patients worldwide.
